SAN FRANCISCO, October 19, 2024 – Gilead Sciences’ (GILD.O) Trodelvy reduced breast cancer progression risk by 38% in a pivotal trial, positioning the drug for earlier treatment use1. The positive results from the ASCENT-03 study could expand Trodelvy’s market opportunity beyond its current third-line indication for metastatic triple-negative breast cancer.
- Trodelvy cut disease progression risk by 38% versus chemotherapy
- Median progression-free survival reached 9.7 months on treatment
- Results support earlier-line treatment expansion for breast cancer
Trial Results and Market Context
In the ASCENT-03 trial, patients receiving Trodelvy achieved a median progression-free survival of 9.7 months without cancer advancement1,2. The antibody-drug conjugate demonstrated superior efficacy compared to standard chemotherapy in treating metastatic triple-negative breast cancer patients.
Trodelvy currently competes in the oncology market alongside other targeted therapies, with the global breast cancer therapeutics market valued at approximately 28 billion annually. The drug generated 1.2 billion in revenue for Gilead in 2023.
Clinical Significance
The ASCENT-03 study represents a potential pathway for Trodelvy to move into earlier lines of treatment for breast cancer patients2. Triple-negative breast cancer affects roughly 15% of all breast cancer patients and typically has fewer treatment options than hormone receptor-positive cancers.
Trodelvy is already approved for third-line or later metastatic triple-negative breast cancer and for certain patients with pre-treated hormone receptor-positive, HER2-negative metastatic breast cancer5. The new data could support regulatory submissions for earlier treatment settings.
Competitive Landscape
The results come as Gilead faces competition from AstraZeneca’s Enhertu and other antibody-drug conjugates in the breast cancer space2. At the European Society for Medical Oncology conference, multiple companies presented competing data for similar patient populations.
Earlier this year, Gilead reported that Trodelvy combined with Merck’s Keytruda reduced breast cancer risk by 35% in another trial, demonstrating the drug’s versatility in combination treatments6. These combination approaches could differentiate Trodelvy in an increasingly crowded market.
Investment Implications
The positive trial results could support Trodelvy’s growth trajectory as Gilead seeks to diversify beyond its HIV franchise. Analysts view the breast cancer indication as a key growth driver for the company’s oncology portfolio.
Regulatory approval for earlier-line use would significantly expand Trodelvy’s addressable patient population and revenue potential. The company has not yet disclosed timeline expectations for regulatory submissions based on the ASCENT-03 data.
Not investment advice. For informational purposes only.
References
1“Gilead’s Trodelvy cuts breast cancer risk by 38% in trial”. Reuters. Retrieved October 19, 2024.
2“At ESMO, AstraZeneca, Gilead square off in breast cancer”. STAT News. Retrieved October 19, 2024.
3“Gilead’s Trodelvy cuts breast cancer risk by 38% in trial”. Reuters Twitter. Retrieved October 19, 2024.
4“Gilead’s Trodelvy cuts breast cancer risk by 38% in trial”. MarketScreener. Retrieved October 19, 2024.
5“ESMO25: Datroway, Trodelvy deliver parallel wins in metastatic TNBC”. FirstWord Pharma. Retrieved October 19, 2024.
6“Gilead’s Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial”. Reuters. Retrieved October 19, 2024.
7“Gilead’s Trodelvy: Redefining Metastatic Breast Cancer Care”. AI Invest. Retrieved October 19, 2024.
8“Trodelvy Use in Early Breast Cancer”. Gilead Medical. Retrieved October 19, 2024.
9“Gilead says Trodelvy reduces risk of disease progression”. MarketScreener. Retrieved October 19, 2024.